MACROGENICS INC
MacroGenics, Inc. (MGNX) is a small‑cap biotechnology company focused on antibody-based and bispecific immunotherapies, primarily in oncology. Investors should know the company leverages engineered Fc domains and dual‑affinity platforms to design targeted treatments; its pipeline spans preclinical to later-stage clinical programmes. As a clinical‑stage specialist with a market cap of about $127.7M, MacroGenics’ value is sensitive to trial readouts, regulatory decisions and partnership news. Biotech firms at this stage typically face significant cash burn and may need to raise capital, which can dilute shareholders. Partnerships and licensing deals can reduce commercial risk and provide non‑dilutive funding, but success depends on clinical efficacy and market adoption. This summary is educational, not personal financial advice — returns are not guaranteed and values can fall as well as rise. Investors should consider their risk tolerance and consult a regulated adviser before making decisions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying MacroGenics' stock with a target price of $10.8, indicating strong growth potential.
Financial Health
MacroGenics is generating strong revenue and cash flow, supported by a high gross margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
ABSCI CORP
ABSCI Corporation is a biotechnology company focused on the discovery and development of targeted immune modulators for the treatment of cancer and other diseases.
Baskets Featuring MGNX
Pharma M&A Targets: Biotech Stocks to Watch 2025
AbbVie is spending $2.7 billion on external R&D, highlighting a major industry trend of large pharmaceutical companies acquiring innovation. This creates a potential opportunity among the smaller biotech firms that are becoming prime acquisition targets.
Published: October 5, 2025
Explore BasketNavigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Published: August 5, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical catalysts ahead
Multiple upcoming trial readouts can materially move the share price; these events are high‑impact but outcomes are binary and can be volatile.
Engineering antibodies
Fc‑engineering and bispecific platforms may create differentiated treatments, though technical and regulatory challenges remain that can delay progress.
Partnerships matter
Collaborations and licensing deals can provide funding and commercial reach, but the benefits depend on execution and market uptake.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
